National Prostate Cancer Audit. Bill Cross June 2015

Similar documents
First Year Annual Report Organisation of Services and Analysis of Existing Clinical Data

Annual Report Results of the NPCA Prospective Audit in England and Wales for men diagnosed from 1 April March 2016

NICE BULLETIN Diagnosis & treatment of prostate cancer

National Breast Cancer Audit next steps. Martin Lee

Measuring the value of healthcare activities. Susan Rollason, Director of Finance and Strategy

Appendix 4 Urology Care Pathways

Informatics in the new NHS : PHE and NCIN 9 months on. Nicky Coombes National Cancer Intelligence Network

Bringing prostate cancer education to regional and rural Australian communities

INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)

Technology appraisal guidance Published: 21 November 2018 nice.org.uk/guidance/ta546

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel

Table 1 Standards and items to set up a PCU: general requirements and critical mass

Delivering stratified follow-up in primary care for Prostate Cancer Patients - The NCL Approach. Dr Elizabeth Babatunde Macmillan GP

London Cancer Alliance

National Standards for Sarcoma Services

National Standards for Sarcoma Services 2009

NCIN Conference Feedback 2015

Prostate Cancer Patients Charter. The care that you deserve

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

PROSTATE CANCER STRATIFIED FOLLOW UP. Hilary Baker Lead CNS for Uro-oncology MSc, BSc, RGN.

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Apples and pears? A comparison of two sources of national lung cancer audit data in England

National Lung Cancer Audit outlier policy 2017

National Standards for Acute Oncology Services

Improving services for upper GI (OG) cancer Application template (Version 2)

IQSS 2019 QCDR and MIPS Measure Specifications

Prostate cancer: diagnosis and treatment

ASST Papa Giovanni XXIII

Commissioning Urology Services in New NHS

An educational guide from Genomic Health

Quality of Life After Modern Treatment Options for Prostate Cancer Ronald Chen, MD, MPH

Horizon Scanning Technology Briefing. Magnetic resonance spectroscopy for prostate cancer. National Horizon Scanning Centre.

United Kingdom and Ireland Association of Cancer Registries (UKIACR) Performance Indicators 2018 report

Pathway specification for urological cancers

18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan

National Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator

National Audit of Breast Cancer in Older Patients. Part of the National Clinical Audit Patient Outcomes Programme Annual Report

Cancer and Data in the New NHS May Di Riley, Director Clinical Outcomes

Fondazione IRCCS Istituto Nazionale dei Tumori

Guideline Prostate cancer: diagnosis and management (update)

Management of Prostate Cancer in Africa. Dr David Anderson Clinical Oncologist Groote Schuur Hospital February 2017

NLCA annual report analysis 2017 (for the population of 2016)

Prostatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London

Consensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director

Health Board/Region: All-Wales

Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer

Cancer of Unknown Primary (CUP) Protocol

Prostate cancer A guide for newly diagnosed men

Low back pain and sciatica in over 16s NICE quality standard

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

Activity Report April 2012 March 2013

The Royal Marsden. Prostate case study. Presented by Mr Alan Thompson Consultant Urological Surgeon

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

DRAFT FOR CONSULTATION. Clinical Commissioning Policy Proposition: Palliative radiotherapy for bone pain

National Cancer Peer Review Programme

Aneurin Bevan University Health Board Breast Cancer and Pregnancy Guideline

Clinical guideline Published: 8 January 2014 nice.org.uk/guidance/cg175

NATIONAL BOWEL CANCER AUDIT The feasibility of reporting Patient Reported Outcome Measures as part of a national colorectal cancer audit

Cancer Outcomes and Services Dataset: Implications for clinical teams

Predictors of use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: Data from a pilot study of 2414 cases

National Bowel Cancer Audit

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)

Cliniques universitaires Saint Luc

Prostate cancer timed clinical pathways

Improving quality of life in men with prostate cancer. Liam Bourke PhD Principal research fellow Sheffield Hallam University

Cancer of Unknown Primary (CUP)

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate

Date Modified: March 31, Clinical Quality Measures for PQRS

National Cancer Intelligence Network Routes to Diagnosis:Investigation of melanoma unknowns

What is Acute Oncology? Kay McCallum Acute Oncology Advanced Nurse Practitioner John Radcliffe Hospital Oxford September 2015

Prostate Cancer UK s Best Practice Pathway

WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

Commissioning Cancer Services. Andy McMeeking RCGP/NCIN Primary Care Workshop, 13 th February 2013

Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer

Survival outcomes for men in rural and remote NSW. Trend in prostate cancer incidence and mortality rates in Australia. The prostate cancer conundrum

Treating localised prostate cancer using freezing (cryotherapy) needles in a targeted area of the prostate

Activity Report July 2014 June 2015

Gynae Cancer Multi Disciplinary Team Patient Information

Improving Outcomes for People with Sarcoma

Active surveillance for low-risk Prostate Cancer Compared with Immediate Treatment: A Canadian cost evaluation

UCLH proposal for Pelvic Cancer Surgical Centre for North and East London. Submission to London Cancer January 2013

SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)

Cancer Service Performance Indicators Round 1 Report. Integrated Cancer Services. January Department of Health

B14/S/b 2013/14 NHS STANDARD CONTRACT FOR PENILE CANCER SECTION B PART 1 - SERVICE SPECIFICATIONS. Service Specification No.

Shared care in prostate cancer: the role of primary care

Proposed Neurosciences National Structure. Accountability Framework Neurological Alliance (Feedback Loop) National Advisory Group (Neurosciences)

Yorkshire Cancer Research Yorkshire Bowel Cancer initiative

Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE

Locally advanced prostate cancer

Activity Report July 2012 June 2013

C o n t e n t s. 2 Introduction. 3 Personal information. 4 Your medical history. 5 PSA results. 7 Healthcare appointments

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases

An Integrated National Strategy for Breast Cancer Audit. Martin Lee Gill Lawrence

ADVICE TO PATIENTS REQUESTING PSA MEASUREMENT FREQUENTLY-ASKED QUESTIONS

2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

A06/S(HSS)b Ex-vivo partial nephrectomy service (Adult)

Upper GI Cancer Network Site-Specific Group. Work Programme/Service Delivery Plan 2011/14

Head and Neck Cancers Data Quality Report Radiotherapy and Chemotherapy Data

Transcription:

National Prostate Cancer Audit Bill Cross June 2015

National Prostate Cancer Audit aim of assessing the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales

National Prostate Cancer Audit The NPCA consists of the following components: 1 2 3 4 5 An organisational audit of service delivery and prostate cancer care in England and Wales An analysis of existing datasets to provide comparative baseline data for the prospective audit A prospective audit of all men newly diagnosed with prostate cancer in England and Wales An audit of patient-reported outcome and experience measures for all patients with localised prostate cancer who are candidates for radical treatment An evaluation of the feasibility of a PSA testing audit in primary care

NPCA Organisational Audit

The organisation of prostate cancer services in England and Wales: results from the organisational audit

Key findings Diagnostic access: availability of MRI

Key findings Radical treatment: availability of surgical techniques

Key findings Support services: availability of personal support

Key findings Support services: palliative care

Key findings Clinical infrastructure: specialist clinics in England and Wales

Key findings Clinical infrastructure: specialist clinics in England and Wales

Analysis of existing data sets

Analysis of existing data sets including patients with prostate cancer in England An analysis of the most recent Cancer Registry data linked at patient level to the administrative English Hospital Episode Statistics (HES) and Patient Episode Data for Wales (PEDW) was planned as a key component of the first year of the NPCA The Health and Social Care Information Centre (HSCIC) was expected to provide the HES data and to carry out the actual record linkage as a trusted third party HSCIC stopped processing requests for data release and record linkage in 2013 Analysis of less recent English Cancer Registry data linked to HES, including men diagnosed with prostate cancer between April 2006 and March 2008 An analysis of English Cancer Registry data of men diagnosed with prostate cancer in 2012 not linked to HES

Definition of performance indicators Disease presentation proportion of men diagnosed with advanced disease proportion of men diagnosed with locally advanced disease Treatment allocation to evaluate over and undertreatment proportion of men with low-risk localised prostate cancer undergoing radical prostate cancer therapy proportion of men with locally advanced disease receiving radical prostate cancer therapy Outcomes of treatment length of hospital stay for radical prostate cancer surgery proportion of patients who had an emergency readmission within 90 days of radical prostate cancer surgery

Completeness of information on disease status

Cancer Registry data 2012 71% 2012 Disease status 2006-08 53% 2012 - More advanced disease Stage & grade

NPCA Prospective Audit

The NPCA dataset consists of only 50 data items in total: 29 items are part of the COSD dataset 1 item is part of the BAUS dataset 20 new items

NPCA Prospective Audit The NPCA dataset comprises three broad categories: NPCA Minimum data set 1: The first category of data items will be collected for all men with newly diagnosed prostate cancer at meeting(s) of the MDT during the initial phase of management NPCA Minimum data set 2: The second category of data items will be collected for all patients who have undergone radical prostatectomy NPCA Minimum data set 3: The third category will be collected for all men for whom external beam radiation therapy or brachytherapy, is planned with or without hormone deprivation therapy

Feasibility study of PSA testing in primary care Provide information about: variation in the "use" of PSA in men who are suspected to have prostate cancer the "yield" of PSA testing the "timeliness" of the diagnostic process The Health and Social Care Information Centre (HSCIC) has launched the Primary Care Pathology (PCP) Project to investigate both the feasibility of primary care pathology data collection and linkage to other data sources such as HES, as part of the care.data programme

Recommendations On the basis of this first Annual Report, we have the following recommendations for providers of prostate cancer services in England and Wales: With respect to the delivery and organisation of prostate cancer services: NHS providers should ensure that multiparametric MRI is more widely available to decrease the likelihood of unnecessary re-biopsy and to improve staging and treatment decision making for patients with potentially curable disease where indicated The availability of high-dose rate brachytherapy should be increased for men with intermediate and high-risk localised or locally advanced prostate cancer The availability of personal support services including cancer advisory centres, sexual function and continence advice, and psychological counselling should be improved Patients with prostate cancer should have access to a CNS with an appropriate background in uro-oncology NHS providers should ensure that patients have access to a joint clinic with a surgeon, an oncologist and a CNS to discuss their treatment options With respect to data collection for the prospective audit: Senior clinicians and other members of the MDT should ensure that complete and accurate data can be submitted to the NPCA for every patient with newly diagnosed prostate cancer, including data on cancer stage and tumour grade